All‐trans retinoic acid (ATRA) in non‐promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low‐dose Ara‐C in three elderly patients with <i>NPM1</i>‐mutated AML unfit for intensive chemotherapy and review of the literature

Abstract

Key Clinical Message Based upon the clinical behavior of three patients, we suggest that the combination of low‐dose Ara‐C and all‐trans retinoic acid may potentially be effective in some elderly patients, unfit for intensive chemotherapy, affected with NPM 1 ‐mutated acute myeloid leukemia without FLT 3 mutations, warranting perspective clinical studies in these selected patients.